Company updateBusinessLine
Sanofi India MD outlines growth plans for rare disease
Positive+19
GreyOak summary
Sanofi India MD Deepak Arora stated the company has no fear of missing out on the GLP-1 category due to its Soliqua product. The company plans to scale access in rare diseases and diabetes, with a new haemophilia therapy launching next year. Public sector purchases contributed nearly 85% growth in the last quarter through government health programs.
What it affects
- Sanofi IndiaSANOFIPositive +19
Plans to scale rare disease and diabetes access.Rolling sentiment Neutral +11
Source
Read the original at BusinessLineMore Sanofi India news
No other recent stories about Sanofi India.
All Sanofi India news →